【百利天恒:伦康依隆妥单抗III期临床完成首例受试者入组】百利天恒公告,公司自主研发的全球首创双抗ADC伦康依隆妥单抗/宜泽康联合PD-1单抗对比含铂化疗联合PD-1单抗用于一线广泛期小细胞肺癌的III期临床试验已于近日完成首例受试者入组。截至目前,该药已在中国和美国开展40余项临床试验,其中III期临床研究19项,已有7项适应症被CDE纳入突破性治疗品种名单,1项适应症被FDA纳入突破性治疗品种名单。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.